Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
ACS Medicinal Chemistry Letters
|
August 20, 2015
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms
Honghe Wan, Gretchen M Schroeder, Amy C Hart, et al.
ACS Medicinal Chemistry Letters
|
November 20, 2020
Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK
Anurag S Srivastava, Soo Ko, Scott H Watterson, et al.
Journal of Medicinal Chemistry
|
November 3, 2015
Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311)
Jennifer X Qiao, Tammy C Wang, Leonard P Adam, et al.
ACS Medicinal Chemistry Letters
|
May 26, 2015
Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors
Ashvinikumar V Gavai, Claude Quesnelle, Derek Norris, et al.
Journal of Medicinal Chemistry
|
October 6, 2021
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders
Huji Turdi, Hannguang Chao, Jon J Hangeland, et al.
Journal of Medicinal Chemistry
|
February 21, 2019
Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P<sub>1</sub>) Modulator Advanced into Clinical Trials
John L Gilmore, Hai-Yun Xiao, T G Murali Dhar, et al.
Journal of Medicinal Chemistry
|
October 12, 2016
Identification of Tricyclic Agonists of Sphingosine-1-phosphate Receptor 1 (S1P<sub>1</sub>) Employing Ligand-Based Drug Design
Hai-Yun Xiao, Scott H Watterson, Charles M Langevine, et al.
Journal of Medicinal Chemistry
|
September 20, 2021
Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design
Ashvinikumar V Gavai, Derek Norris, George Delucca, et al.
Journal of Medicinal Chemistry
|
September 2, 2016
Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers
Scott H Watterson, George V De Lucca, Qing Shi, et al.
Journal of Medicinal Chemistry
|
October 23, 2019
Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy
David Marcoux, James J-W Duan, Qing Shi, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
ACS Medicinal Chemistry Letters
|
August 20, 2015
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms
Honghe Wan, Gretchen M Schroeder, Amy C Hart, et al.
ACS Medicinal Chemistry Letters
|
November 20, 2020
Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK
Anurag S Srivastava, Soo Ko, Scott H Watterson, et al.
Journal of Medicinal Chemistry
|
November 3, 2015
Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311)
Jennifer X Qiao, Tammy C Wang, Leonard P Adam, et al.
ACS Medicinal Chemistry Letters
|
May 26, 2015
Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors
Ashvinikumar V Gavai, Claude Quesnelle, Derek Norris, et al.
Journal of Medicinal Chemistry
|
October 6, 2021
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders
Huji Turdi, Hannguang Chao, Jon J Hangeland, et al.
Journal of Medicinal Chemistry
|
February 21, 2019
Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P<sub>1</sub>) Modulator Advanced into Clinical Trials
John L Gilmore, Hai-Yun Xiao, T G Murali Dhar, et al.
Journal of Medicinal Chemistry
|
October 12, 2016
Identification of Tricyclic Agonists of Sphingosine-1-phosphate Receptor 1 (S1P<sub>1</sub>) Employing Ligand-Based Drug Design
Hai-Yun Xiao, Scott H Watterson, Charles M Langevine, et al.
Journal of Medicinal Chemistry
|
September 20, 2021
Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design
Ashvinikumar V Gavai, Derek Norris, George Delucca, et al.
Journal of Medicinal Chemistry
|
September 2, 2016
Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers
Scott H Watterson, George V De Lucca, Qing Shi, et al.
Journal of Medicinal Chemistry
|
October 23, 2019
Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy
David Marcoux, James J-W Duan, Qing Shi, et al.
Page
of 7